Spyre Therapeutics (SYRE) announced Spyre has been added to the Nasdaq Biotechnology Index effective prior to market open, Monday, December 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- TD says Spyre has ‘superior TL1A program’ after Teva data
- Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
- Spyre Therapeutics initiated with a Hold at JonesResearch
- Spyre Therapeutics announces first participants dosed in Phase 1 trial
- Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50